Scancell Share Discussion Threads

[bermudashorts] 15/11/2024 09:21

Chilltime

I'm fully aware of the potential for the Genmab milestone and we have discussed this before. You still maintain that it will extend the cash runway for a few months and I have previously explained to you that Scancell's cash burn is approaching £20m pa and according to Trinity Delta the milestone will be £2.5m - do the maths.

Then there is the potential for a second GlyMab deal - but LD has previously stated that up front payments for future mAb deals are likely to be similar to the Genmab deal and Scancell have already received £1m. So yes, it has the potential to help but we don't know yet whether it will happen, nor the amount and it can't be relied upon.

As for other deals, I think and hope that they're unlikely before commencement of the SCIB1/i/scib1 phase 2/3. If Scancell are to optiimise valuations IMO they need to have a randomised SCIB study under their belts and a phase 1/2 for SC134 to demonstrate superiority over BMS's candidate and having come this far it would be so disappointing to see them deal too early. Regarding Modi, we simply don't have enough information from Scancell to make any judgement call.

Now look at the funding requirements going forwards when they are running large trials both here and in the US. You believe Scancell will be able to fund this by non-dilutive funding via deals but we can't ignore the possibility that it's simply too early for deals to cover all funding requirements. Against that backdrop it's perfectly reasonable to point out that Scancell need to hit timescales so any raise is post results and the timings are tight with recent slippage.

Should add that I'm very much encouraged by the appointment of Phil L'Huillier with his track record.

[chilltime] 15/11/2024 09:13

Flugel

I concur but I think they have archived it to something like subscriber status.

They are there ready should Scancell need them.

Scancell is not a hype retail bucket shop cap in hand share. Funds already own over 50% of the company.

Some retail hype shares in this space have hardly any fund ownership, largely retail driven on share prices.

[chilltime] 15/11/2024 08:41

Just for mebtion as I was hunting for the funds looking to get in further down the line.

It seems proactive investors archive earlier interviews to sign in status, so it’s in there.

But on checking a later interview post the glymab exclusive deal she does mention being in talks with another company for another glymab deal.

AGM she says broad commercial interest in SC134. Talks re deals on Glymabs.

So Genmab phase 1 pending

Decision re exclusive Glymab deal

SC134

Remaining Glymabs talks re deals.

[gazza] 15/11/2024 08:36

Is that your post or Bermuda's? I can't see any going on about fundraising. We all know Scancell will need more funds as one point, it's no big secret.

[flugelhorn] 15/11/2024 08:23

It was just after last year's fund raise time !

[chilltime] 15/11/2024 08:17

If anyone wants comments made by the CFO or Lindy listed, then I’ll happily point to interviews etc where they can be found.

On the funds waiting to get in bigger further down the line, I have struggled to find that one, but I’m 100% sure, I’ll try to find it.

[chilltime] 15/11/2024 08:13

I dropped into LSE via a search a week ago ago. I rarely read there, the particular exchange was quite vicious and extensive there over the point.

Topic about no HLA patients in the Scib1 trial, when Scancell said there are in news.

Hence I pointed out the AGM comment having listened to the AGM this week.

Lindy

“Virtually no HLA patients in Scib1 trial”

So the answer is yes there are a small number of HLA types in the Iscib trial.

Reading between the lines.

Scancell did say HLA types preferring to wait for Iscib, at that time the stop at 27 was apparent.
Clearly the strategy changed (complete scib1 to 43) so the HLA types went into Scib1 hence 32 jumped to 41 patients.
That’s my thought process in why it changed, perhaps on advice from the panel.

[chilltime] 15/11/2024 07:58

Gazza

This 2 days ago

Scancell now need to ensure they stick to their own revised timescales for release of trial results so they are not forced to raise funds ahead of potential inflection points.

No mention of cash runway extensions, which the CEO has mentioned.

Genmab milestone which would likely extend it a few months.

Exclusive review Glymab. Deal due before the end of Jan, Yes or no.

Other Glymab deals, all have interest.

So potentially a 6 to 12 months cash extension there

SC134 interest must be in a ball park value for Scancell to consider handing it over. That’s the one they are excited about, so I can’t see the up front there being less than 10’s of millions.

Bermuda sold a chunk on Modi news a while ago and is waiting for scib1/iscib data.

Nothing wrong with that. In my view scib1 data will cause big interest, big companies are already talking to Scancell waiting for data.

Then you have Glymab news x 3 pending likely before iscib data. SC134 with broad commercial interest and a poorly served area could produce a considerable up front deal.

A deal re scib could come pre Iscib data. An NDA will keep them in the loop about Iscib progress.

Any deal though would have to be at a level Scancell consider good value or they will run it themselves.

They won’t decide until data is in (unless a cracking offer comes in) talks already in play.

On the timelines and things stacked up even if they did raise I’d be thinking 50p plus anyway.

Peeling right back to the last raise Lindy said funds there wanting larger amounts further down the line.

They are not lacking potential backers.

[sci102] 15/11/2024 07:25

Just seen it. Exactly the right people are certainly attending London Life Sciences Week. Fingers in gordian knots.

[ivyspivey] 15/11/2024 07:18

They have reported on Linked in that there will be a few atending

[sci102] 15/11/2024 07:14

Are they attending?

[bermudashorts] 15/11/2024 07:13

........and also makes much more commercial sense to announce news to coincide with Jefferies and London Life Sciences Week.

[sci102] 15/11/2024 07:04

No RNS. I was expecting she'd want to announce before the new CEO takes over. If there is one next week, that is going to be a good sign of more rational and experienced people taking over management as it is good practice to boost a new ceo's momentum with positive announcements.

[sci102] 15/11/2024 06:51

It sucks to be in a position to hope that LD is a victim of her own BS but the actual data is good.

[sci102] 15/11/2024 06:29

ClownT. She did not say the trial will stop/declared succesful at 27 responses. She said that if the response remains high they will not need to recruit 43 (they are now at 42) to demonstrate their target. She also said that the trial is configured to show 70%.

That's 30-31 responses.

Most importantly, LD has said a lot of things that were proven beyond doubt to be BS. For example in the same month of that interview (and in that interview) they published an RNS that said they expect to complete recruitment by end of 2023, which was impossible.

By the way, what happened to the nonsense you were supporting that patients that were eligible for scib1 were waiting for iscib1+? Then again, I can't fully blame you as LD did say that exactly.

[ivyspivey] 15/11/2024 06:27

Morning Gazza,
That is a real issue here of sheer number of repeated posts and certain posters wanting to swamp the board for nefarious reasons to prevent any balanced debate and those seeking info are basically prevented from doing so.
Those of us who have been here a long time remember that SCLP have a history of missed deadlines therefore simply quoting the words of the BoD need to be put in a historical context.

[gazza] 14/11/2024 23:55

CT, "You posted the other day going on about funding and fund raises ignoring what the CFO and Lindy have said"What was the post number, I can't seem to find it?

[gazza] 14/11/2024 23:47

Bermuda, I sincerely hope people reflect on your comment.."I'll continue to rely on the helpful posters here and on lse and when they ask questions I'll try to reciprocate."We are quite privileged to have a group of people here and on LSE with such a wide range of expertise - immunology, the biotech sector, the pharmaceutical sector, the stock market, data analysis, patent process, clinical trial protocol etc, etc. also, to those who perhaps don't have the specialist knowledge but prepared to put in the grunt work and doing research. This combined knowledge has to be beneficial for those willing to share.

[chilltime] 14/11/2024 23:46

Bermuda

You seem vexed over basic exchanges.

You posted the other day going on about funding and fund raises ignoring what the CFO and Lindy have said numerous times.

So I pointed out the 3 things they have said are pending or potentially pending.
Milestone payment Genmab
Up front on the other glymab if the partner goes ahead.
SC 134 and other Glymab deals.

You are one of the last I’d expect to forget details.


At the AGM and other events basic questions or misunderstandings featured, EG one getting confused if a partial response is 70%, 70% being the target.

You also asked if Scancell ever said Scib1 would stop at 27, which was something repeated on here many times, which you clearly forgot.

So I gave the answer, with the link as you often ask for the reference.

So if you as a regular contributor are forgetting potentially important details then it’s surely best to clarify points.

Another example, not you, some seemed, post AGM to try and push Q1 25 as the likely Scib1 data timeline, when the AGM content clearly states Q4.

The only obvious reason it would be Q1 is partial responses not following the average trend as expected.

So until no news comes by year end re Scib1 data it’s still Q4.

[inanaco] 14/11/2024 20:09

you said

Must admit I learned a lot last night and happy to say I feel vindicated in my thoughts here so am very happy with his responses which clarified a lot for me.

only he hardly mentioned Scancell .. because he cannot discuss the trial

[inanaco] 14/11/2024 20:06

by the way Ivy the other day you said you had been vindicated ? what did you mean by that

[inanaco] 14/11/2024 20:03

what has leaked Ivy .. ?

[inanaco] 14/11/2024 20:02

I have no idea ... as that result will have no impact on releasing on ORR data in Q4

you never know ISCIB1 first 15 Simon 1 could be released

[ivyspivey] 14/11/2024 19:58

Bermuda well I hope we get some news tomorrow as this has been a leaky ship lately.
Hopefully we can get actual news as II find the endless Willy waving of certain posters pontificating on about pretending they know what is actually going on quite nauseating